about
Background and Current Treatment of Squamous Cell Carcinoma of the Anus.Biosimilar Oncology Drugs in Europe: Regulatory and Pharmacovigilance Considerations.The Perspectives of Haematological Cancer Patients on Tissue Banking.Panobinostat as Pan-deacetylase Inhibitor for the Treatment of Pancreatic Cancer: Recent Progress and Future Prospects.Chordoma: The Quest for Better Treatment Options.Identifying and Targeting the Cause of Cancer is Needed to Cure Cancer.A Combination of Two Receptor Tyrosine Kinase Inhibitors, Canertinib and PHA665752 Compromises Ovarian Cancer Cell Growth in 3D Cell Models.Real-World Treatment Patterns for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer in Europe and the United States.Liquid Chromatography-Mass Spectrometry/Mass Spectrometry Analysis and Pharmacokinetic Assessment of Ponatinib in Sprague-Dawley Rats.Second-line Treatments for Advanced Gastric Cancer: A Network Meta-Analysis of Overall Survival Using Parametric Modelling Methods.Efficacy and Safety Results of the Afatinib Expanded Access Program.Spectroscopic and Imaging Characteristics of Pigmented Non-Melanoma Skin Cancer and Melanoma in Patients with Skin Phototypes III and IV.The Cost Impact of Lenalidomide for Newly Diagnosed Multiple Myeloma in the EU5.Health-Related Quality of Life of Patients with Acute Myeloid Leukemia: A Systematic Literature Review.Patient Reported Outcomes (PROs) as Part of Value-Based Care Can Shape Therapy Guidelines: Impact on Emerging Targeted Agents and Immunotherapy Protocols in Resource-Limited Regions.DNA Mutations May Not Be the Cause of Cancer.A Review of Fulvestrant in Breast Cancer.Network Meta-analysis of Progression-Free Survival and Overall Survival in First-Line Treatment of BRAF Mutation-Positive Metastatic Melanoma.Impact of CYP3A4*18 and CYP3A5*3 Polymorphisms on Imatinib Mesylate Response Among Chronic Myeloid Leukemia Patients in Malaysia.Health-Related Quality of Life as a Prognostic Measure of Clinical Outcomes in Renal Cell Carcinoma: A Review of the CheckMate 025 Trial.Cutaneous CD8+ Cytotoxic T-Cell Lymphoma Infiltrates: Clinicopathological Correlation and Outcome of 35 Cases.Switching from an LHRH Antagonist to an LHRH Agonist: A Case Report of 10 Finnish Patients with Advanced Prostate Cancer.Bone Marrow Necrosis in Newly Diagnosed Acute Leukemia: Two Case Reports and Review of the Literature.Topical Application of a Galenical Formulation for the Management of Everolimus-Induced Mucositis in Patients with Metastatic Cancer: a Retrospective Study.Contemporary Management of Metastatic Gastrointestinal Stromal Tumors: Systemic and Locoregional Approaches.Concurrent Pilomatrix Carcinoma and Diffuse Large B-Cell Lymphoma.Erratum to: Chordoma: The Quest for Better Treatment Options.Factors Impacting Treatment Choice in the First-Line Treatment of Colorectal Cancer.Intra-Abdominal and Abdominal Wall Desmoid Fibromatosis.A Phase I, Dose-Escalation Trial of Pazopanib in Combination with Cisplatin in Patients with Advanced Solid Tumors: A UNICANCER Study.Living with Cancer: Through the Eyes of the Patient and the Physician.Oesophageal Adenocarcinoma: A Patient and Physician's Perspective.Qualitatively Comparing the Support Needs of People with Cancer Based on Their History of Anxiety/Depression.The Patient Perspective on Living with Acute Myeloid Leukemia.Phase I Study of Anti-GM2 Ganglioside Monoclonal Antibody BIW-8962 as Monotherapy in Patients with Previously Treated Multiple Myeloma.
P1433
Q50897271-439C99A0-BD94-4966-BD4B-84ED791E1F0DQ51034561-382CF481-2446-45BB-AF8E-94E14A85A587Q51034570-54877105-2261-42A6-A773-C20C6881CDDFQ51034578-F47E8E96-7CCD-45A1-9B6E-629169A9C788Q51034581-A3EBB432-E66E-4455-91A6-F8B1635866BAQ51034587-73B2F9A0-6506-4CC7-8C0A-5EC862D78E7CQ51110603-7F8150B2-D855-4C3B-A22F-507E3B268462Q51333026-F7F2FB96-2B12-4E3D-B3FD-65D71A2316FEQ52145020-C9654B62-B14C-4AF1-87D5-99DD58E0B76FQ52585940-20CD22EB-0AE5-4B8E-A2A2-AE0B0CD835FEQ52763503-AEC38E1A-FA0B-4997-B93D-CAADE2E94BCAQ52891819-AF4A863B-0C26-44B8-A002-1D6EA9E513A7Q53543459-A5462A52-6DB5-4B5D-A95C-B728F520D82BQ53543462-28F0280D-040A-4CE7-84CB-5598F0635F19Q53711726-4797EDCF-C18A-4BE7-85E0-E19663099B1EQ53725947-A63DBC69-7799-4F02-BBD9-605640AF3FB1Q53733893-04E240AF-D9AA-47C3-9D27-5D22345CCC5CQ53747880-6991931D-EF7F-4774-9BF2-19C3D004D626Q53803475-2D0681BB-8429-40AD-83FB-5B6F165BE621Q54169331-7074F571-30B2-4B63-BBA9-6EA8BBAD342EQ54255260-CECF037D-6D2C-49FF-BE6E-A6EA1BA77EEEQ54414647-029577A7-46CB-488E-9D4B-76706619674AQ54660373-B262C276-70A0-4310-B2BC-1534AB10247EQ54858266-7D536C82-99D4-4875-84A1-78BFAF06EA3FQ54863183-8E648418-A5B1-46E6-A876-4D282FDC3FD3Q54913030-C053E7F2-61B9-4D0F-A9A9-E52B1B9E58D3Q54981802-BAB5FF0D-A4C0-4925-8BDE-658BB3A5C6CBQ55007703-66C0EA92-D655-4FE6-9507-5A8ED731E3D2Q55052699-37EEAC53-B284-40CF-BB63-E4C3477FEE27Q55064836-74A20F0F-43AE-473C-B6DA-ACAACAA60E4FQ55086170-0D7AD54C-8AD4-4F68-A844-060A415AC109Q55094610-38CA1402-D34C-427A-A322-1B827CC93899Q55101092-724BCFEA-F22F-4307-8B96-89964F583E78Q55112789-52206B30-AA88-4F74-A2A2-F298F50C7181Q55140257-0EA41211-5BB4-44FC-B67A-99BB6E96FA41
P1433
description
Academic journal published by ...... cluding cancer and carcinogens
@en
academisch tijdschrift
@nl
name
Oncology and Therapy
@en
Oncology and Therapy
@nl
type
label
Oncology and Therapy
@en
Oncology and Therapy
@nl
prefLabel
Oncology and Therapy
@en
Oncology and Therapy
@nl